Fosun Pharma: It is expected that the net profit attributable to the parent company will be a loss of 220-280 million yuan in 2025.

Fengdong Pharmaceutical announced that it is expected to incur a net loss attributable to shareholders of the listed company of 220 million to 280 million yuan in the 2025 fiscal year, compared to a loss of 1.329 billion yuan in the same period the previous year. During the reporting period, the company's production and operation activities were carried out normally, but due to changes in industry policies and market conditions, the sales volume or prices of some products have declined, resulting in a decrease in the profits contributed by these products.